Norbert Pardi
- Infectious Diseases top 0.2%
- SARS-CoV-2 and COVID-19 Research 22
- Viral gastroenteritis research and epidemiology 11
- Immunology top 0.5%
- Immunotherapy and Immune Responses 16
- Animal Science and Zoology top 0.5%
- Animal Virus Infections Studies 13
- Molecular Biology top 1%
- RNA Interference and Gene Delivery 34
- Virology top 2%
-
- Virus-based gene therapy research 14
-
- Influenza Virus Research Studies 9
- Herpesvirus Infections and Treatments 6
- Co-authors
- Drew WeissmanMichael J. HoganFrederick PorterHiromi MuramatsuKatalin KarikóYing K. TamBarbara L. MuiThomas D. Madden
- Partner nations
- United StatesHungaryGermany
In The Last Decade
Norbert Pardi
73 papers receiving 8.3k citations
Hit Papers
Peers
Comparison fields: 5 of 141
- Infectious Diseases 3.0k
- Immunology 2.5k
- Animal Science and Zoology 768
- Molecular Biology 5.1k
- Virology 247
Countries citing papers authored by Norbert Pardi
This map shows the geographic impact of Norbert Pardi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Norbert Pardi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Norbert Pardi more than expected).
Fields of papers citing papers by Norbert Pardi
This network shows the impact of papers produced by Norbert Pardi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Norbert Pardi. The network helps show where Norbert Pardi may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Norbert Pardi, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2025 | 0 | |
| 3 | 2025 | 0 | |
| 4 | 2024 | 12 | |
| 5 | 2024 | 1 | |
| 6 | mRNA vaccines for infectious diseases — advances, challenges and opportunitiesbreakdown → | 2024 | 67 |
| 7 | Development of an mRNA-lipid nanoparticle vaccine against Lyme diseasebreakdown → | 2023 | 46 |
| 8 | 2023 | 1 | |
| 9 | 2023 | 39 | |
| 10 | 2023 | 0 | |
| 11 | 2023 | 9 | |
| 12 | 2023 | 72 | |
| 13 | 2023 | 11 | |
| 14 | Single immunizations of self-amplifying or non-replicating mRNA-LNP vaccines control HPV-associated tumors in micebreakdown → | 2023 | 87 |
| 15 | 2022 | 27 | |
| 16 | 2022 | 57 | |
| 17 | Chimeric spike mRNA vaccines protect against Sarbecovirus challenge in micebreakdown → | 2021 | 93 |
| 18 | 2020 | 44 | |
| 19 | PECAM-1 directed re-targeting of exogenous mRNA providing two orders of magnitude enhancement of vascular delivery and expression in lungs independent of apolipoprotein E-mediated uptakebreakdown → | 2018 | 154 |
| 20 | 2018 | 101 |
About Norbert Pardi
Norbert Pardi is a scholar working on Infectious Diseases, Animal Science and Zoology, Virology, Immunology and Parasitology, having authored 82 papers that have together received 8.5k indexed citations. Recurring topics across this work include RNA Interference and Gene Delivery (34 papers), SARS-CoV-2 and COVID-19 Research (22 papers), Immunotherapy and Immune Responses (16 papers), Virus-based gene therapy research (14 papers), Animal Virus Infections Studies (13 papers), Viral gastroenteritis research and epidemiology (11 papers), Influenza Virus Research Studies (9 papers) and Herpesvirus Infections and Treatments (6 papers). The work is most often cited by research in Infectious Diseases (3.0k citations), Immunology (2.5k citations), Animal Science and Zoology (768 citations), Molecular Biology (5.1k citations) and Virology (247 citations). Norbert Pardi has collaborated with scholars based in United States, Hungary and Germany. Frequent co-authors include Drew Weissman, Michael J. Hogan, Frederick Porter, Hiromi Muramatsu, Katalin Karikó, Ying K. Tam, Barbara L. Mui, Thomas D. Madden, Michael J. Hope and Steven Tuyishime. Their work appears in journals such as Nature Communications, Vaccine, Molecular Therapy, npj Vaccines and Journal of Controlled Release.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.